Most people read drug patents like theyre reading product specs. Thats the mistake.
If you want to understand where a generic challenge is headedor where a brands next life-cycle move is likely to landyou dont start with the active ingredient. You star…

The biosimilar patent dance isnt a formalityits a strategy war.
If youre a biologics sponsor or a biosimilar applicant, the rules may look procedural. But the outcomes are anything but. The patent dancebuilt around timing, notice, and litigation trig…

Generic manufacturers dont wait for exclusivitythey engineer it.
In the Paragraph IV world, the 180-day window isnt a prize you win by filing a lawsuit. Its a strategic asset you buildthrough timing, litigation posture, manufacturing readiness, and a…

The Patent Dance Is No Longer a DanceIts a Strategy. Heres the Playbook.
If youve been in biotech long enough, youve heard the phrase: the patent dance. But the real story isnt choreographyits leverage.
In the biologics and biosimilars world, the BP(C)…

Big Pharma isnt talking about the one dataset that can quietly change your supply-chain forecast.
Its not a new molecule. Its not a blockbuster launch. Its something far less glamorousand far more predictive: drug patent data.
In a world where forecast…

Patent cliffs dont just threaten revenuethey can quietly reshape supply chains.
When a blockbuster drugs patent protection expires, the market doesnt simply get cheaper. It gets messier: new entrants, shifting pricing dynamics, changing manufacturing…

Generic drug makers are facing a quiet crisisone that doesnt show up in headlines as bankruptcy or fraud, but in something far more corrosive: margin compression. If youre a pharma investor, operator, or supplier, the story behind the numbers is increa…

Branded pharmas revenue model is under siegeand its not just one villain. Its a whole ecosystem of forces that, together, are turning launch, defend, repeat into launch, delay, discount, and pray.
In a recent piece by DrugPatentWatch, the argument is b…

Generic drug competition isnt just about filing. Its about timing, intelligence, and decoding the FDAs Orange Book.
If youve ever wondered how some generic manufacturers seem to consistently arrive at market right when exclusivity endswhile others miss…

Biopharma hiring isnt just about finding talent. Its about finding the right talent for the right IP workat the right time.
Heres the uncomfortable truth: many organizations still treat IP hiring like a generic functionpost a role, screen for keywords,…